Figure 3 LEBRI_EASI_ANIMATION_v4.mp4 (17.64 MB)
Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis
Version 2 2024-05-07, 09:05
Version 1 2024-04-24, 07:24
media
posted on 2024-04-24, 07:24 authored by Adis Journals on Behalf of, Eric Simpson, Marjolein de Bruin-Weller, H. Chih Ho Hong, Delphine Staumont-Sallé, Andrew Blauvelt, Kilian Eyerich, Melinda Gooderham, Mona Shahriari, Lotus Mallbris, Amber Reck Atwater, Maria Jose Rueda, Zhuqing Liu, Yuxin Ding, Helena Agell, Jonathan I. Silverberg
Article full text
The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.
The above animation represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
